HomeClinical TopicsFDA approves new drug for Duchenne muscular dystrophy

FDA approves new drug for Duchenne muscular dystrophy

On Feb. 9, the U.S. Food and Drug Administration (FDA) approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (the most common type of muscular dystrophy). Read more 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content